Aclidinium Bromide
The bromide salt form of aclidinium, a long-acting inhaled bronchodilator used for the ongoing management of COPD. It is administered via a dry powder inhaler twice daily and works by keeping the airways relaxed throughout the day and night. Patients should continue to carry a short-acting rescue inhaler for sudden breathing difficulties.
Peso molecular
564,6000 g/mol
TPSA
112,00 Ų
Áreas terapéuticas
Mecanismo de acción
Activates beta-2 adrenergic receptors on bronchial smooth muscle, stimulating adenylyl cyclase and increasing intracellular cAMP. This relaxes airway smooth muscle and produces bronchodilation.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Activates beta-2 adrenergic receptors on bronchial smooth muscle, stimulating adenylyl cyclase and increasing intracellular cAMP. This relaxes airway smooth muscle and produces bronchodilation.
Estructura 2D
Cite this structure
Embed this structure
SMILES
O=C(O[C@H]1C[N+]2(CCCOc3ccccc3)CCC1CC2)C(O)(c1cccs1)c1cccs1.[Br-]
InChI
InChI=1S/C26H30NO4S2.BrH/c28-25(26(29,23-9-4-17-32-23)24-10-5-18-33-24)31-22-19-27(14-11-20(22)12-15-27)13-6-16-30-21-7-2-1-3-8-21;/h1-5,7-10,17-18,20,22,29H,6,11-16,19H2;1H/q+1;/p-1/t20?,22-,27?;/m0./s1
Molecular Formula
C26H30BrNO4S2
HBD / HBA
1 / 7
Enlaces Rotables
10
Átomos Pesados
34
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Preguntas frecuentes
The bromide salt form of aclidinium, a long-acting inhaled bronchodilator used for the ongoing management of COPD. It is administered via a dry powder inhaler twice daily and works by keeping the airways relaxed throughout the day and night. Patients should continue to carry a short-acting rescue inhaler for sudden breathing difficulties.
Activates beta-2 adrenergic receptors on bronchial smooth muscle, stimulating adenylyl cyclase and increasing intracellular cAMP. This relaxes airway smooth muscle and produces bronchodilation.
Yes, Aclidinium Bromide is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL551466. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 11519741. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="aclidinium-bromide"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/aclidinium-bromide/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/aclidinium-bromide/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/aclidinium-bromide/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="aclidinium-bromide"></drugfyi-drug>